Gilead terminates early study for BTLA agonist in rheumatoid arthritis due to efficacy concerns

Gilead Sciences (Foster City, California, USA) has terminated a Phase Ib clinical trial of GS-0272, a selective B and T Lymphocyte Attenuator (BTLA) agonist being evaluated in adults with rheumatoid arthritis (RA), according to the ClinicalTrials.gov registry. As per the listing, the GS-0272 clinical trial was terminated "due to lack of efficacy" with 55 participants enrolled and no results posted publicly. The news may mark the effective end of the lead asset from Gilead's USD 405 million acquisition of UK-based autoimmune biotech MiroBio, carried out in 2022.

The NCT06031415 trial was a multicenter, randomized, placebo-controlled multiple ascending dose study, that enrolled 55 patients with rheumatoid arthritis and was evaluating the safety, pharmacokinetics and preliminary efficacy of GS-0272.

The decision removes what had been positioned as a mechanistically novel entry into the crowded RA space — one premised on immune checkpoint agonism rather than the cytokine blockade or kinase inhibition that defines most approved therapies. Gilead has yet to provide specific data readouts or commentary on the reasons for the termination. Gilead's 2022 acquisition of MiroBio was framed explicitly around the potential of immune checkpoint agonism — exploiting inhibitory receptors such as BTLA and PD-1 to suppress pathological immune activation in autoimmune disease, rather than broadly blocking inflammatory mediators downstream. GS-0272, then known as MB-272, was the flagship asset of that deal, and its termination now raises pointed questions about the return on that investment.

BTLA functions as an inhibitory co-receptor on T and B cells, and its ligand — herpesvirus entry mediator (HVEM) — is broadly expressed, suggesting that agonizing this axis could dampen autoreactive immune responses with a degree of selectivity that cytokine-targeted therapies cannot achieve. The hypothesis is scientifically coherent. The clinical translation, however, has proven elusive across the field, and Gilead's exit from the BTLA program adds to a growing list of checkpoint agonist programs that have struggled to advance beyond early-phase studies in autoimmune indications.

Gilead is not entirely abandoning the MiroBio-derived pipeline. GS-0151, a PD-1 agonist also originating from the acquisition and formerly designated MB-151, remains in Phase I development for RA. The company appears to be concentrating its immune checkpoint agonist ambitions on PD-1, where the mechanistic rationale in autoimmunity is arguably better established and the competitive landscape, while active, has produced more encouraging early signals.

---

Spot something wrong? Report an issue with this article